![]() ![]() All individuals with the immunocompromising conditions listed below should receive an additional dose as part of their primary series.These individuals need stronger protection because their immune systems respond differently to vaccines than other people without these conditions. Clinics are also available in First Nations communities. How to book: Book online (pharmacy is recommended or AHS clinic), or call Health Link at 811.Hematopoietic stem cell transplant (HSCT) recipients and CAR T-cell therapy recipients are recommended to consult with their physician regarding COVID-19 vaccine spacing.A shortened interval is not permitted for the other eligible groups. A shortened interval of at least 3 calendar months between the previous bivalent booster dose (or infection) and the additional bivalent booster dose will be permitted for residents of long-term care facilities and other congregate care living settings to administer the additional dose to as many people as possible in a timely manner.A longer interval leads to a better immune response against COVID-19 infection that is expected to last longer. At least 6 months since the last dose or most recent COVID-19 infection.Individuals taking certain medications for autoimmune diseases including rituximab, ocrelizumab, ofatumumab and methotrexate.Recipients of active cancer treatment (chemotherapy, immunotherapy or targeted therapies), excluding those receiving only hormonal therapy, radiation therapy or surgery.Individuals with chronic kidney disease receiving regular dialysis.Transplant recipients, including solid organ and hematopoietic stem cell transplants.Recipients of immunosuppressive therapies (for example, anti-B cell therapies, high-dose systemic corticosteroids, alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents).Individuals with advanced untreated HIV infection or acquired immunodeficiency syndrome (AIDS).Individuals with moderate to severe primary immunodeficiency (for example, DiGeorge syndrome, Wiskott-Aldrich syndrome).Recipients of chimeric antigen receptor (CAR) T-cell therapy.Adults 18 years and older with the following eligible immunocompromising conditions:.Residents of long-term care facilities and other congregate care living settings who are 18 years and older.Eligibility: People at higher risk of severe outcomes who received a bivalent booster dose on or after September 21, 2022, including:.Additional bivalent booster for select groups 18+.Both the BA.4/5 bivalent and the BA.1 bivalent vaccines provide a broad immune response against circulating variants.The bivalent vaccines trigger a stronger immune response and provide additional protection against both Omicron and the original SARS-CoV-2 virus strain.The bivalent vaccines authorized for use in Canada include the Moderna bivalent and Pfizer-BioNTech bivalent vaccines.Some community medical clinics are also offering COVID-19 vaccines and can be contacted directly.If your local pharmacy is not listed in the booking system, contact them directly or find a pharmacy near you. Many pharmacies are also accepting walk-in appointments.How to book: Book online (pharmacy is recommended or AHS clinic) or call Health Link at 811.A longer interval leads to a better immune response against COVID-19 infection that is expected to last longer.If you choose not to get this bivalent booster dose, you cannot get an additional booster dose of another vaccine.If you received an original (monovalent) mRNA vaccine or a non-mRNA vaccine as your booster dose, you are eligible for a one-time bivalent booster dose following the recommended dose interval.Check the "Additional bivalent booster for select groups 18+" section below to see if you are eligible to receive an additional bivalent booster dose.Select groups of Albertans 18+ at high risk of severe outcomes from COVID-19 infection are eligible to receive an additional bivalent booster dose.Most Albertans who received a bivalent booster dose on or after September 21, 2022, are considered up to date and another booster dose is not recommended at this time.Eligibility: People 12 years and older who completed a primary series, including a mix of mRNA COVID-19 vaccines (Pfizer-BioNTech or Moderna) and/or non-mRNA COVID-19 vaccines (Novavax, Janssen or AstraZeneca) and have not received a bivalent mRNA COVID-19 vaccine booster dose since September 21, 2022.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |